N-Acetylimidazolidinone → [2,4-Bis(2-oxoimidazolidin-1-yl)phenyl][4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone
반응식
Br[C:2]1[CH:7]=[C:6](Br)[CH:5]=[CH:4][C:3]=1[C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]2[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=2)[CH2:13][CH2:12]1)=[O:10].C([N:28]1[CH2:32][CH2:31][NH:30][C:29]1=[O:33])(=O)C>>[O:33]=[C:29]1[NH:30][CH2:31][CH2:32][N:28]1[C:2]1[CH:7]=[C:6]([N:30]2[CH2:31][CH2:32][NH:28][C:29]2=[O:33])[CH:5]=[CH:4][C:3]=1[C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]2[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=2)[CH2:13][CH2:12]1)=[O:10]참가 물질
3
실험 절차
Using (2,4-dibromophenyl) [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (258 mg) described in Preparation Example 237 and 1-acetylimidazolidin-2-one (219 mg) and by the reaction and treatment in the same manner as in Example 638, the title compound (71 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-a65243d1f9154ae39be0ef15e31991cc
- 출처 데이터셋
- uspto-grants-2014_08